Ben Urich

In this engaging discussion, Ben Urich, Senior Director of Health Outcomes at Prime Therapeutics, dives into the world of GLP-1 drugs like Ozempic and Wegovy. He reveals fascinating insights on the explosive growth in their use, highlighting persistence rates and why most users stop. Ben addresses the costs of these medications and the financial impact on employers. The conversation also touches on side effects, ongoing studies for new therapeutic uses, and the potential of 30 new drugs in the pipeline, painting a vivid picture of the future of weight-loss medicine.